Linda Louie - AMGEN DRN Vice President - Finance, Chief Accounting Officer

AMGN34
  

BRL 54.18  0.16  0.29%   

  Insider
Vice President - Finance, Chief Accounting Officer. We currently do not have informatin regarding Linda Louie. This executive tanure with AMGEN DRN is not currenlty determined.
Age: 47  Insider Since 2020      
805 447 1000  https://www.amgen.com

AMGEN DRN Management Efficiency

AMGEN DRN has return on total asset (ROA) of 10.46 % which means that it generated profit of $10.46 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 123.31 %, meaning that it generated $123.31 on every $100 dollars invested by stockholders. AMGEN DRN management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 36.52 B in total debt. AMGEN DRN has a current ratio of 1.5, which is within standard range for the sector. Debt can assist AMGEN DRN until it has trouble settling it off, either with new capital or with free cash flow. So, AMGEN DRN's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AMGEN DRN sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AMGEN to invest in growth at high rates of return. When we think about AMGEN DRN's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

INSIDER Since

Rodrigo CordeiroABC BRASIL PN
N/A
Carlos MedeirosVALE ON NM
2019
Livia SantanaABC BRASIL PN
N/A
Patricia BentesVALE ON NM
2019
Eduardo FilhoVALE ON NM
2019
Rodrigo MontemorABC BRASIL PN
N/A
Isabella AlbuquerqueVALE ON NM
2017
Edgard NetoABC BRASIL PN
N/A
Claudio AlvesVALE ON NM
2019
Brendon HopkinsABC BRASIL PN
N/A
Fernando FernandesABC BRASIL PN
N/A
Rodrigo GalvaoABC BRASIL PN
N/A
Ricardo RochaABC BRASIL PN
N/A
Marcello SpinelliVALE ON NM
2019
Gustavo AlmeidaABC BRASIL PN
N/A
Carlos SilvaABC BRASIL PN
N/A
Daniel OliveiraABC BRASIL PN
N/A
Luiz NetoABC BRASIL PN
N/A
Marco MastroeniABC BRASIL PN
N/A
Fernando IunesABC BRASIL PN
N/A
Felipe TamburusABC BRASIL PN
N/A
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. AMGEN DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 24200 people. AMGEN DRN (AMGN34) is traded on Sao Paolo Stock Exchange in Brazil and employs 24,200 people.

AMGEN DRN Leadership Team

Elected by the shareholders, the AMGEN DRN's board of directors comprises two types of representatives: AMGEN DRN inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AMGEN. The board's role is to monitor AMGEN DRN's management team and ensure that shareholders' interests are well served. AMGEN DRN's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AMGEN DRN's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda Louie, Vice President - Finance, Chief Accounting Officer
Frank Herringer, Independent Director
Francois Carbonnel, Independent Director
Rebecca Henderson, Independent Director
Annette Such, Chief Accounting Officer
Sanders Williams, Independent Director
Vance Coffman, Lead Independent Director
David Reese, Executive Vice President - Research and Development
Tyler Jacks, Independent Director
Brian McNamee, Executive Vice President - Full Potential Initiatives
Gregory Garland, Independent Director
Charles Holley, Independent Director
Esteban Santos, Executive Vice President Operations
Jonathan Graham, Senior Vice President General Counsel, Secretary
Sean Harper, Executive Vice President - Research and Development
Ellen Kullman, Independent Director
Frank Biondi, Independent Director
Arvind Sood, IR Contact Officer
David Meline, Executive Vice President, Chief Financial Officer
Ronald Sugar, Independent Director
Stuart Tross, Senior Vice President - Human Resources
Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee
Murdo Gordon, Executive Vice President of Global Commercial Operations
Peter Griffith, Chief Financial Officer, Executive Vice President
Wanda Austin, Independent Director
Robert Eckert, Lead Independent Director
Madhavan Balachandran, Executive VP of Operations
Lori Johnston, Senior Vice President - Human Resources
Brian Druker, Independent Director
Cynthia Patton, Senior Vice President Chief Compliance Officer
Greg Garland, Independent Director
Robert Williams, Independent Director
Amy Miles, Independent Director
Judith Pelham, Independent Director
David Baltimore, Independent Director
Fred Hassan, Independent Director
David Piacquad, Senior Vice President - Business Development
Anthony Hooper, Executive VP of Global Commercial Operations

AMGEN Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AMGEN DRN a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in AMGEN DRN without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module

Pair Trading with AMGEN DRN

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AMGEN DRN position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AMGEN DRN will appreciate offsetting losses from the drop in the long position's value.

Moving together with AMGEN DRN

+0.79PFIZ34PFIZER DRNPairCorr
The ability to find closely correlated positions to AMGEN DRN could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AMGEN DRN when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AMGEN DRN - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AMGEN DRN to buy it.
The correlation of AMGEN DRN is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AMGEN DRN moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AMGEN DRN moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AMGEN DRN can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. Note that the AMGEN DRN information on this page should be used as a complementary analysis to other AMGEN DRN's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for AMGEN Stock analysis

When running AMGEN DRN price analysis, check to measure AMGEN DRN's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AMGEN DRN is operating at the current time. Most of AMGEN DRN's value examination focuses on studying past and present price action to predict the probability of AMGEN DRN's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move AMGEN DRN's price. Additionally, you may evaluate how the addition of AMGEN DRN to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Please note, there is a significant difference between AMGEN DRN's value and its price as these two are different measures arrived at by different means. Investors typically determine AMGEN DRN value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AMGEN DRN's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.